Table 4.
Efficacy against variants of interest and variants of concern
| Total number (N=16 973)* | BBV152 (N=8471) | Placebo (N=8502) | Vaccine efficacy, % (95% CI) | |
|---|---|---|---|---|
| All variants | 79 (0·5%) | 18 (0·2%) | 61 (0·7%) | 70·8% (50·0 to 83·8) |
| B.1.617.2 (delta) | 50 (0·3%) | 13 (0·2%) | 37 (0·4%) | 65·2% (33·1 to 83·0) |
| B.1.617.1 (kappa) | 11 (0·1%) | 1 (<0·1%) | 10 (0·1%) | 90·1% (30·4 to 99·8) |
| B.1.1.7 (alpha) | 4 (<0·1%) | 1 (<0·1%) | 3 (<0·1%) | .. |
| Other† | 14 (0·1%) | 3 (<0·1%) | 11 (0·1%) | 73·0% (−2·2 to 95·2) |
| All variants (severe COVID-19) | 4 (<0·1%) | 0 | 4 (<0·1%)‡ | .. |
Data are n (%) unless otherwise stated. Data include per-protocol population only. In those participants who met the definition for symptomatic COVID-19 and were PCR-positive an additional nasopharyngeal swab for genotyping was collected. Nasopharyngeal swabs with cycle threshold value greater than 30 were not genotyped. We were unable to retrieve the complete genome from six swab samples that were sequenced (all in the placebo group), and these samples weren't included in the analysis.
79 of 130 positive cases in the per-protocol set were sequenced.
Other pangolin variants detected were Asp614Gly (n=7), B.1.36 (n=2), B.1.1.419, B.1.153, B.1.351, B.1.618, and A.1 (all n=1 each).
Alpha, kappa, delta, and unclassified variants (n=1 each).